Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (Q88506528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

title

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Jang Hwan Cho

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

James J Collins

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Wilson W Wong

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

26 April 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

volume

173

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

page(s)

1426-1438.e11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

Ligation of the CD5 or CD28 molecules on resting human T cells induces expression of the early activation antigen CD69 by a calcium- and tyrosine kinase-dependent mechanism.

25 March 2020

cites work

1 reference

12 December 2020

Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response

1 reference

12 December 2020

AP-1 function and regulation

1 reference

12 December 2020

The roles of CD28 and CD40 ligand in T cell activation and tolerance

1 reference

12 December 2020

Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines

1 reference

12 December 2020

Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation

1 reference

12 December 2020

Improving the efficacy of antibody-based cancer therapies

1 reference

12 December 2020

Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model.

1 reference

12 December 2020

Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer

1 reference

12 December 2020

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

1 reference

12 December 2020

The B7 family revisited

1 reference

12 December 2020

Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus

1 reference

12 December 2020

Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor.

1 reference

12 December 2020

CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype

1 reference

12 December 2020

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

12 December 2020

A Synthetic Coiled-Coil Interactome Provides Heterospecific Modules for Molecular Engineering

1 reference

12 December 2020

A simple and sensitive method for measuring tumor-specific T cell cytotoxicity

1 reference

12 December 2020

Longer action means better drug: tuning up protein therapeutics

1 reference

12 December 2020

Cell surface signaling molecules in the control of immune responses: a tide model.

1 reference

12 December 2020

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

12 December 2020

Strategies for extended serum half-life of protein therapeutics

1 reference

12 December 2020

Inducible apoptosis as a safety switch for adoptive cell therapy

1 reference

12 December 2020

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

12 December 2020

A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor

1 reference

12 December 2020

Antibody therapy of cancer

1 reference

12 December 2020

CD4⁺T cells: differentiation and functions

1 reference

12 December 2020

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

1 reference

12 December 2020

SYNZIP protein interaction toolbox: in vitro and in vivo specifications of heterospecific coiled-coil interaction domains

1 reference

12 December 2020

Redirecting gene-modified T cells toward various cancer types using tagged antibodies

1 reference

12 December 2020

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

1 reference

12 December 2020

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

1 reference

12 December 2020

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

12 December 2020

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

12 December 2020

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

1 reference

12 December 2020

Epithelial ovarian cancer experimental models.

1 reference

12 December 2020

Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.

1 reference

12 December 2020

Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

1 reference

12 December 2020

Building better drugs: developing and regulating engineered therapeutic proteins.

1 reference

12 December 2020

T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing

1 reference

12 December 2020

Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo

1 reference

12 December 2020

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

12 December 2020

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

1 reference

12 December 2020

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

1 reference

12 December 2020

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

12 December 2020

Are natural killer cells superior CAR drivers?

1 reference

12 December 2020

Advantages and applications of CAR-expressing natural killer cells

1 reference

12 December 2020

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

1 reference

12 December 2020

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

1 reference

12 December 2020

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

1 reference

12 December 2020

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

1 reference

12 December 2020

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

1 reference

12 December 2020

Versatile strategy for controlling the specificity and activity of engineered T cells

1 reference

12 December 2020

Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

1 reference

12 December 2020

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

1 reference

12 December 2020

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

1 reference

12 December 2020

Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor

1 reference

12 December 2020

T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells

1 reference

12 December 2020

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

1 reference

12 December 2020

Toxicities of chimeric antigen receptor T cells: recognition and management

1 reference

12 December 2020

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts

1 reference

12 December 2020

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

1 reference

12 December 2020

Toxicity and management in CAR T-cell therapy

1 reference

12 December 2020

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.

1 reference

12 December 2020

Therapeutic T cell engineering

1 reference

12 December 2020

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy

1 reference

12 December 2020

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

1 reference

12 December 2020

10.1016/J.CELL.2018.03.038

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29706540%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference